Zydus Lifesciences Limited’s has received approval from the United States Food and Drug Administration (USFDA) to market Lenalidomide Capsules, USP 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The company has received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength. USRLD: Revlimid®.
- Read more about Zydus receives final approval from the USFDA for Lenalidomide Capsules
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/zydus-receives-final-approval-from-the-usfda-for-lenalidomide-capsules
No comments:
Post a Comment